Table 2—

Changes in weight and risk factors during the study

Time−2 months0 months18 months36 monthsP value
Weight (kg)P111.9 ± 16.0−14.3 (−12)−9.6 (8.4)−7.2 (−6.3)0.028
O110.7 ± 17.9−14.5 (−13)−11.7 (10.4)−9.4 (−8.3)
Waist circumference (cm)P119 ± 10.9−12−9−5.40.032
O119 ± 12.1−12−12−7.7
A1C (%)P6.28 ± 0.64−0.48−0.34−0.51NS
O6.32 ± 0.93−0.54−0.43−0.69
Fasting glucose (mmol/l)P6.27 ± 1.54−0.95−0.45−0.32NS
O6.44 ± 1.83−1.1−0.67−0.49
Fasting insulin (pmol/l)P114 ± 58.3−45−28−12NS
O116 ± 65.3−48−35−26
C-peptid (nmnol/l)P1.02 ± 0.39−0.19−0.03+0.160.09
O1.10 ± 0.43−0.21−0.1+0.05
Total cholesterol (mmol/l)P6.02 ± 1.08−1.2−0.13−0.46NS
O5.91 ± 1.26−1.2−0.36−0.46
LDL cholesterol (mmol/l)P3.77 ± 0.94−0.80−0.12−0.38NS
O3.71 ± 1.04−0.75−0.29−0.34
HDL cholesterol (mmol/l)P1.15 ± 0.26−0.07+0.11+0.06NS
O1.13 ± 0.26−0.05+0.06+0.04
Triglycerides (mmol/l)P2.50 ± 1.41−0.94−0.34−0.43NS
O2.36 ± 1.24−0.89−0.32−0.38
BT sys (mmHg)P144 ± 17.3−12−7.2−8.2NS
O144 ± 19.3−13−8.2−7.8
BT dia (mmHg)P90.7 ± 10.4−7.6−4.8−4.7NS
O90.8 ± 11.6−7.2−5.1−3.7
  • Data are n (%) or means ± SD. The abdominally obese subjects were randomised after 2 months of VLED (from month −2 to month 0) to receive either orlistat (O) or placebo (P). Values at the various times are absolute changes from initial values (month −2) calculated from the intention-to-treat population. Minus indicates reduction from initial values and plus increment. Body weight changes are also given in percentage (in parentheses). P values are given for the absolute changes after 36 months between orlistat and placebo. The time effect at 36 months versus 0 month is significant for all parameters (P < 0.001).